cas 1023742-13-3|| where to buy O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

Nom du produit:O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

IUPAC Name:O-[2-(tert-butoxy)ethyl]hydroxylamine

Unité d'emballage	Stock disponible	Prix($)
CM325604-100g	in stock	ŪŪƚ
CM325604-500g	in stock	ƴƐȖŪ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1023742-13-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1023742-13-3; Formule moléculaire:C6H15NO2; Point de fusion:-; Code SMILES:NOCCOC(C)(C)C; Densité:

: Numéro de catalogue:CM325604; Poids moléculaire:133.19; Point d'ébullition:; N° Mdl:; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: Encorafenib plus Binimetinib; U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.